BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 18575432)

  • 1. [Digestive neoplasms and bevacizumab].
    Bennouna J
    J Chir (Paris); 2008 Jan; 145 Spec No 1():1S16-20. PubMed ID: 18575432
    [No Abstract]   [Full Text] [Related]  

  • 2. Drug insight: antiangiogenic therapies for gastrointestinal cancers--focus on monoclonal antibodies.
    Reinacher-Schick A; Pohl M; Schmiegel W
    Nat Clin Pract Gastroenterol Hepatol; 2008 May; 5(5):250-67. PubMed ID: 18382435
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bevacizumab: one treatment for all the seasons?
    Gelibter AJ; Di Segni S; Zeuli M; Cognetti F
    J Clin Oncol; 2008 Jan; 26(3):511; author reply 511-2. PubMed ID: 18202430
    [No Abstract]   [Full Text] [Related]  

  • 4. [Bevacizumab. Progress in cancer therapy by antiangiogenesis].
    Krämer I; Lipp HP
    Med Monatsschr Pharm; 2006 Jul; 29(7):249-54; quiz 255-6. PubMed ID: 16866078
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combined treatment of a juxtapapillary retinal capillary haemangioma with intravitreal bevacizumab and photodynamic therapy.
    Ziemssen F; Voelker M; Inhoffen W; Bartz-Schmidt KU; Gelisken F
    Eye (Lond); 2007 Aug; 21(8):1125-6. PubMed ID: 17545966
    [No Abstract]   [Full Text] [Related]  

  • 6. Current role of bevacizumab in colorectal cancer.
    Saltz L
    Clin Adv Hematol Oncol; 2009 Jun; 7(6):375-6. PubMed ID: 19606071
    [No Abstract]   [Full Text] [Related]  

  • 7. Safety of bevacizumab with fluoropyrimidine-based regimens for first-line treatment of metastatic colorectal cancer.
    Tyagi P
    Clin Colorectal Cancer; 2006 Sep; 6(3):189-91. PubMed ID: 17026787
    [No Abstract]   [Full Text] [Related]  

  • 8. Bevacizumab in the treatment of ovarian cancer.
    Han ES; Monk BJ
    Expert Rev Anticancer Ther; 2007 Oct; 7(10):1339-45. PubMed ID: 17944559
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Addition of bevacizumab to chemotherapy for treatment of solid tumors: similar results but different conclusions.
    Ocaña A; Amir E; Vera F; Eisenhauer EA; Tannock IF
    J Clin Oncol; 2011 Jan; 29(3):254-6. PubMed ID: 21149670
    [No Abstract]   [Full Text] [Related]  

  • 10. Angiogenesis inhibition with bevacizumab and the surgical management of colorectal cancer.
    Thornton AD; Ravn P; Winslet M; Chester K
    Br J Surg; 2006 Dec; 93(12):1456-63. PubMed ID: 17115389
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Endogenous stimulators and inhibitors of angiogenesis in gastrointestinal cancers: basic science to clinical application.
    Sund M; Zeisberg M; Kalluri R
    Gastroenterology; 2005 Dec; 129(6):2076-91. PubMed ID: 16344073
    [TBL] [Abstract][Full Text] [Related]  

  • 12. What is the risk of bowel perforation associated with bevacizumab therapy in ovarian cancer?
    Han ES; Monk BJ
    Gynecol Oncol; 2007 Apr; 105(1):3-6. PubMed ID: 17383545
    [No Abstract]   [Full Text] [Related]  

  • 13. Antitumor benefits from two antiangiogenesis agents.
    Expert Rev Anticancer Ther; 2003 Aug; 3(4):425-6. PubMed ID: 12934654
    [No Abstract]   [Full Text] [Related]  

  • 14. Angiogenesis of breast cancer.
    Schneider BP; Miller KD
    J Clin Oncol; 2005 Mar; 23(8):1782-90. PubMed ID: 15755986
    [No Abstract]   [Full Text] [Related]  

  • 15. Success of bevacizumab trials raises questions for future studies.
    Tuma RS
    J Natl Cancer Inst; 2005 Jul; 97(13):950-1. PubMed ID: 15998941
    [No Abstract]   [Full Text] [Related]  

  • 16. Preoperative radiotherapy and bevacizumab for angiosarcoma of the head and neck: two case studies.
    Koontz BF; Miles EF; Rubio MA; Madden JF; Fisher SR; Scher RL; Brizel DM
    Head Neck; 2008 Feb; 30(2):262-6. PubMed ID: 17685450
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bevacizumab: an angiogenesis inhibitor for the treatment of solid malignancies.
    Shih T; Lindley C
    Clin Ther; 2006 Nov; 28(11):1779-802. PubMed ID: 17212999
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Anti-angiogenic therapy for gastrointestinal tumours].
    Graepler F; Gregor M; Lauer UM
    Z Gastroenterol; 2005 Mar; 43(3):317-29. PubMed ID: 15765305
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Progression-free survival in bevacizumab-based first-line treatment for patients with metastatic colorectal cancer: is it a really good end point?
    Montagnani F; Migali C; Fiorentini G
    J Clin Oncol; 2009 Oct; 27(28):e132-3; author reply e134-5. PubMed ID: 19720898
    [No Abstract]   [Full Text] [Related]  

  • 20. Chemotherapy as palliation in advanced colon cancer.
    J Support Oncol; 2007 Feb; 5(2):66. PubMed ID: 17348358
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.